$LUNG

Pulmonx Corp

Pulmonx is a commercial-stage medical technology company that provides minimally invasive treatments for patients with severe emphysema who remain profoundly symptomatic despite medical management and do not want or are ineligible for surgery. Its main solution combines the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the LungTraX Platform. The Zephyr Valve is used to reduce lung hyperinflation; Chartis assesses collateral ventilation, and LungTraX analyzes CT scans to help physicians identify and plan treatment candidates. Pulmonx also manufactures the AeriSeal System, a synthetic polymer foam designed to close collateral air channels. Pulmonx makes most of its money from sales of Zephyr Valves and delivery catheters. It also earns money from Chartis balloon catheters, usage fees and console sales, and from the LungTraX Platform. The company sells through a direct sales organization in the United States and uses direct and distributor-based sales models internationally. Pulmonx is headquartered in Redwood City, California.

3
0
0

No SEC Form 4 filings for $LUNG in the last 30 days.

See all $LUNG insider activity →
Med

Pulmonx Corporation (LUNG) Reports 75.8% Collateral Ventilation Conversion

Pulmonx (LUNG) reported 75.8% of patients converted from CV+ to CV− after AeriSeal treatment in the CONVERT Trial. 88.9% of evaluable patients achieved significant target-lobe volume reduction with Zephyr Valves. AeriSeal is under pivotal evaluation, with CONVERT II results needed for U.S. PMA application.

Pulmonx 3Q 2026: Revenue $22.84M, Net income ($8.39M), EPS ($0.19) — 10-Q Summary

Pulmonx reported Q3 2026 revenue of $22.84M, up 6.2% YoY, with net loss narrowing to $8.39M. EPS improved to ($0.19) from ($0.34). Growth driven by Zephyr Valve procedures, offset by lower U.S. volumes and paused China shipments. Nine-month revenue declined 2.5% to $66.2M. China shipments expected to resume in early 2027.

Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30%

Genmab (GMAB) shares rose 33% after reporting positive Phase 3 results for its cancer drug. Pulmonx (LUNG) and Axogen (AXGN) shares gained over 30% on strong quarterly results. OrthoPediatrics (KIDS) and Replimune (REPL) also reported improved financials, driving their stock prices up. Specific financial data and guidance were provided by each company.

LUNG sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 3 news stories mentioning LUNG (Pulmonx Corp). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.

Recent LUNG coverage spans earnings, financial news and market movers.

What's driving LUNG

  • Positive clinical conversion and target-lobe reduction data support the Zephyr treatment pathway and keep AeriSeal’s pivotal readout on track.

    tradingview.com · Nov 17, 2026

  • Quarterly results show modest revenue growth and narrowing losses, which may slightly improve sentiment.

    tradingview.com · Nov 3, 2026

  • Improved financials and raised guidance support continued rally.

    rttnews.com · Oct 28, 2026

  • Stifel kept a Buy rating on Pulmonx with a $4 price target, suggesting 102% upside from the last close. The company reported 6.8% YoY U.S. sales growth and 18% reduced operating expenses, with a 76.2% gross margin.

    tradingview.com · Oct 28, 2026

  • Pulmonx Corporation's average stock price target increased from $3.4 to $3.7, with estimates ranging from $2.5 to $5 per share, according to 5 analysts. This implies an 87% potential upside from the Oct. 27 closing price. The consensus rating remains 'Buy' with 3 Buys, 2 Holds, and 0 Sells.

    tradingview.com · Oct 28, 2026

AlphAI scores every news story that mentions LUNG with an AI model for sentiment and relevance, and aggregates insider trades from Pulmonx Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $LUNG

Score
$GMABHighAI 8/10

Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30%

Genmab (GMAB) shares rose 33% after reporting positive Phase 3 results for its cancer drug. Pulmonx (LUNG) and Axogen (AXGN) shares gained over 30% on strong quarterly results. OrthoPediatrics (KIDS) and Replimune (REPL) also reported improved financials, driving their stock prices up. Specific financial data and guidance were provided by each company.

Pulmonx (LUNG) Q3 2026 Earnings Call Transcript

Pulmonx (LUNG) reported Q3 2026 revenue of $22.8M, up 6% YoY, marking a return to growth. U.S. revenue rose 7% to $14.9M, while international revenue increased 5% to $7.9M. The company reduced adjusted EBITDA loss by 60% to $3.5M and expects full-year revenue of $90M-$92M. Gross margin improved to 76%, and operating expenses decreased 18% YoY to $24.9M. Pulmonx aims to expand its market through AeriSeal and restart commercial activity in China.

$LUNGMedEarnings

Pulmonx Reports Third Quarter 2026 Financial Results

Pulmonx Corp (LUNG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Pulmonx Reports Third Quarter 2026 Financial Results Redwood City, CA - October 27, 2026 – Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today reported financial results for the thi

Why is Pulmonx stock sliding today?

Pulmonx (LUNG) stock fell 10.1% in pre-market trading to $2.05, with no clear catalyst. The decline follows a recent rally from its 52-week low, and profit-taking is a possible reason. The company's Q2 2026 earnings showed a 5% revenue decline, and analysts remain cautious. Broader market weakness also contributed to the drop.

Top Biotech Gainers: UPC Cuts Loss, CPIX Gains Ahead Of Q2 Results, AUTL Builds Commercial Momentum

Biotech gainers on Monday included Universe Pharmaceuticals (UPC), which reported six-month ended March 31, 2026 revenue of $9.03 million and net loss of $1.55 million, and shares rose about 99% to $6.48. Cumberland Pharma (CPIX) rose over 38% ahead of Q2 results after a $100 million branded portfolio sale. Autolus (AUTL) gained about 22% on preliminary Q2 Aucatzyl net product revenue of about $45 million. Other movers included Pulmonx (LUNG), SL Science (SLBT), CAMP4 (CAMP), and Beyond Air (XAI

Related tickers